Biogen Inc. BIIB
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · biogen.com
Biogen Inc. is a global biopharmaceutical company based in Cambridge, Massachusetts, focused on discovering, developing, and delivering therapies for neurological, specialized immunology, and rare diseases. The company's marketed portfolio includes treatments for multiple sclerosis (TECFIDERA, TYSABRI, AVONEX), spinal muscular atrophy (SPINRAZA), Alzheimer's disease (LEQEMBI, co-commercialized with Eisai), Friedreich's Ataxia (SKYCLARYS), and ALS (QALSODY).
Key ratios
FreeCashFlowOnSale TTM 0.21
FreeCashFlowOnSale 2025 0.21
FreeCashFlowOnSale 2024 0.28
FreeCashFlowOnSale 2023 0.13
NetIncomeMargin TTM 0.13
NetIncomeMargin 2025 0.13
NetIncomeMargin 2024 0.17
NetIncomeMargin 2023 0.12
ReturnOnAssets TTM 0.06
ReturnOnAssets 2025 0.06
ReturnOnAssets 2024 0.06
ReturnOnAssets 2023 0.05
ReturnOnEquity TTM 0.07
ReturnOnEquity 2025 0.07
ReturnOnEquity 2024 0.1
ReturnOnEquity 2023 0.08
Recent news
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
2026-06-17 · GlobeNewswire
Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
2026-06-04 · GlobeNewswire